Meeting
2019 ASCO Annual Meeting
No relationship of axillary total tumor load (TTL) by PCR (OSNA) in early breast cancer and local and distant clinical outcomes.
Authors
Jose Ales-Martinez
Complejo Asistencial de Ávila, Ávila, Spain
Jose Ales-Martinez , Raquel Tur , Juan Parra , Jaime Ceballos , Elena Filipovich , Beatriz Segovia , Rafael Revestido , ANA De Castro , Paz Blanco , María José Velasco , Maria Rocio Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 564)
DOI
10.1200/JCO.2019.37.15_suppl.564
Abstract #
564
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
First Author: Ciara Catherine Maria O'Sullivan
Poster
2023 ASCO Annual Meeting
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
First Author: Luca Mastrantoni
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2023 ASCO Annual Meeting
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
First Author: Rebecca Arielle Shatsky